Walleye Capital’s ClearPoint Neuro CLPT Stock Holding History

Walleye Capital’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-24,700	Closed	-$277K	–	2325
2021 Q4	$277K	Buy	+24,700	New	+$370K	0.01%	1297

Other funds holding CLPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TFCM

Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Walleye Capital's CLPT Position: Q1 2022 in Review

Walleye Capital sold out of ClearPoint Neuro (CLPT) in Q1 2022, closing a stake of 24,700 shares — an estimated $277K sold.

Walleye Capital first reported a position in CLPT in Q4 2021 and held it in 1 quarter. The position peaked at $277K in Q4 2021. 64 funds tracked by Wall St. Rank hold CLPT as of Q1 2022.

Walleye Capital reported no remaining ClearPoint Neuro position as of Q1 2022 after selling out during the quarter.
Walleye Capital sold 24,700 ClearPoint Neuro shares in Q1 2022, an estimated $277K.
Walleye Capital first reported a position in ClearPoint Neuro in Q4 2021 and held it in 1 quarter.
Walleye Capital's ClearPoint Neuro position peaked at $277K in Q4 2021.
64 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q1 2022.

Based on Walleye Capital's 13F filing for Q1 2022, filed 16 May 2022.